Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet
0
Biotech IPOs surged at the start of 2024, but the rest of the year will depend on Fed rate cuts. Meanwhile, doctors using VR and AI to hone their skills.